Charlotte Pain Management Center Celebrates Over 25 Years of Providing Relief
Port Charlotte, Florida, June 19, 2025 (GLOBE NEWSWIRE) -- Charlotte Pain Management Center, known for its commitment to personalized pain treatment, celebrates over 25 years of delivering compassionate care and clinical excellence in Southwest Florida. Established in 1997, it has become a cornerstone of hope and healing for those dealing with chronic pain. Dedicated to restoring quality of life, it combines medical expertise, innovation, and patient advocacy.
Charlotte Pain Management Center'It's difficult to put into words what this milestone means to us,' says Nancy Harris, RN, founder and CEO of Charlotte Pain Management Center. 'Personally, this clinic isn't just a business. It's a calling. I grew up believing you help people whether you know them or not, and that principle has guided everything we do here. After so many years, to still be here and still making a difference, we're beyond grateful. Our patients trust us with some of the hardest parts of their lives, and that trust means everything to us.'
Charlotte Pain Management Center was founded on the belief that no one should have to live in persistent pain without access to meaningful relief. Catering to patients suffering from nerve pain, neuropathy, bone and joint issues, and complex chronic conditions, the clinic offers interventional and non-interventional treatment plans that are as individualized as the patients themselves. The center employs a whole-patient approach that blends cutting-edge and compassionate care. This is evident in its services, from spinal cord stimulation and radiofrequency ablation to advanced joint and nerve block injections.
The team at Charlotte Pain Management Center includes experienced physicians, medical professionals, and behavioral health specialists who collaborate to address the physical, emotional, and psychological aspects of pain. Besides its team of experts, the clinic is also known for its commitment to accessibility. It works with patients who may lack insurance or resources, ensuring that no one is turned away without options.
'Where others might only offer one-size-fits-all procedures, we build sustainable and personalized care paths,' Harris says. That reputation for providing relief where others couldn't have helped solidified the clinic as a vital resource in the region. However, it's worth noting that it took grit and resilience for Charlotte Pain Management Center to establish itself in the field.
The founder began her career managing home health services and medical practices, where she witnessed firsthand the gap in long-term, effective pain care. Her vision to create a more humane and more effective approach led to the founding of the center. Unfortunately, the founder faced some monumental challenges within her personal life.
Yet, even during the darkest times, Harris never considered closing the doors. Her connection to her patients and the knowledge that many had nowhere else to turn drove her to push forward. 'I couldn't let them down,' she recalls. 'We're often the last stop. Shutting down wasn't an option.'
Emerging from that period with renewed focus, Harris revitalized the clinic. She hired a new physician who brought fresh capabilities and advanced techniques to the team, reestablished essential services like cancer pain treatment, and invested in the latest technologies, including state-of-the-art C-arm imaging equipment. The center expanded its programs to include comprehensive neuropathy protocols and innovative, lesser-known modalities. The outcome was a rebirth both in operations and in mission.
As it celebrates over 25 years of serving the community, Charlotte Pain Management Center remains committed to staying at the forefront of the medical field. Harris remarks: 'Technology and treatments will continue to advance, but our priority will always be to deliver patient-centered care.'
Media Contact
Name: Nancy Harris, RN, BSN
Email: info@painpc.com
The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. Reliance on any information provided in this article is solely at your own risk.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
Dr. Oz on the future of US healthcare: 'There is a new sheriff in town'
Listen and subscribe to Decoding Retirement on Apple Podcasts, Spotify, or wherever you find your favorite podcasts. In an exclusive interview on Yahoo Finance's Decoding Retirement podcast, Dr. Mehmet Oz, the administrator of the Centers for Medicare & Medicaid Services (CMS), discussed the financial and operational challenges facing the US healthcare system. Ultimately responsible for the healthcare of 66 million Medicare beneficiaries, 78 million people enrolled in Medicaid and the Children's Health Insurance Program (CHIP), and millions more in Affordable Care Act health plans, Oz weighed in on issues ranging from new Medicaid work requirements to Medicare Advantage fraud. This embedded content is not available in your region. Medicaid work requirements The Congressional Budget Office (CBO) estimates that the One Big Beautiful Bill Act (OBBBA) could reduce federal Medicaid spending by $793 billion over the next decade and lead to 10.9 million fewer enrollees by 2034. This is partially attributed to the Medicaid work requirements the OBBA will make states enforce for certain adult enrollees by Jan. 1, 2027, which generally involves 80 hours per month of work, community service, education, or work programs. The CBO estimates the requirement will decrease coverage by 5.2 million enrollees by 2034. Concerns about red tape are not hypothetical: In Georgia, where work requirements are already in place, reports show that otherwise eligible workers are losing coverage simply because of paperwork hurdles. However, Oz said that technology and digital solutions could help beneficiaries comply with the rules without losing coverage. 'We've already launched two pilots in Louisiana and Arizona with good results so far,' Oz said. The new digital process, he explained, uses a smartphone app to verify work automatically through payroll providers. "The people running it are the same folks who fixed the passport system in America,' he said. 'Ninety-one percent of people on Medicaid have smartphones. You tap on the smartphone within the app where you're working. Let's say you're an Uber driver, it knows that ADP does your payroll, and so it asks you permission, 'Can I contact ... ADP and ask them about your hours?' You say yes, and boom, ... the entire process is less than seven minutes." Oz, however, stopped short of addressing some key questions, such as how many people might lose coverage under the current system or whether administrative barriers will unfairly affect millions before the new technology is fully in place. Medicare Advantage and 'upcoding' Oz weighed in on the controversy swirling around Medicare Part C, better known as Medicare Advantage. About 33 million people are enrolled in these private plans, offered by companies such as UnitedHealth Group (UNH) and CVS Health (CVS). Medicare Advantage allows enrollees to receive Part A (hospital), Part B (medical), and, when bundled, Part D (prescription drug) coverage in one plan. The program has been under a harsh spotlight. Earlier this month, UnitedHealth confirmed it is under federal investigation. And a Wall Street Journal story detailed how some Medicare Advantage providers allegedly exploited the system through questionable or outright fraudulent billing practices. 'The whole point of launching Medicare Advantage was to give seniors options," Oz said. "But in the middle of all this, if it turns out that Medicare Advantage is costing us a lot more than fee-for-service, you're violating the whole premise.' The big problem is 'upcoding," the practice of inflating the severity of patients' conditions to trigger higher government payments. 'In Medicare Advantage, I do think that there's been an ability for the private companies to game the coding system,' Oz said. 'Instead of just saying, 'I got what I got, I'm going to take care of them and be honest about how sick they are,' they expertly devised tactics to upcode to pretend the patients were sicker than they really were. That got them more money.' Oz said CMS is now taking aggressive steps to recover funds and send a message: 'We have a process called RADV that allows us to go back to the late teens and, for the first time, audit Medicare Advantage companies,' he said. 'Based on what we find, we're going to pull money back from them. We expect it will be billions and billions of dollars. But more importantly, we're sending a message to the industry: Listen, I want you to succeed. I want you to thrive, but not at the expense of the American taxpayer.' Concern about Medicare's financial future According to the 2025 OASDI Trustees Report, Medicare Part B premiums are expected to rise 11.6% in 2026 to $206.50 a month — the steepest single-year increase in nearly a decade. At the same time, the Medicare Hospital Insurance Trust Fund, which finances Part A, is projected to run dry in 2033. If Congress doesn't intervene, that insolvency would trigger an automatic 11% cut in covered hospital services. Oz called the looming Part B increase a 'major concern,' citing the surge in prescription drug prices as the primary culprit. 'But there are other things,' Oz said, 'that are in Part B as well that we believe we have control over and we could get to be more efficient.' Rather than promising immediate regulatory fixes, Oz said his agency should work directly with industry. 'A lot of this is hearing the stakeholders and then pushing back on what you've heard and then letting them actually come up with some ideas themselves,' he said. 'We've gone back to all of them and said, we need better answers. What you're doing now is making you a lot of money, and you can do that for another year or two — and then the bottom's going to fall out.' 'The … Trustees Report predicts that [Part A] is bankrupt in 2033,' Oz added. 'That's three years shorter than we thought a month ago. And in their worst-case scenario, it goes bankrupt in [2029].' For context, Medicare Part A is primarily funded through a dedicated payroll tax under the Federal Insurance Contributions Act, or FICA. The total Medicare tax rate is 2.9% of wages — typically split evenly between employee and employer. That means 1.45% is withheld from your paycheck, and your employer contributes the other 1.45% on your behalf. Navigating Medicare open enrollment As Medicare's annual open enrollment period approaches — beginning Oct. 15 for 2026 coverage — millions of beneficiaries will face one of the biggest financial decisions of the year: whether to stick with their current plan or make a change. Most Medicare beneficiaries never switch plans, even though premiums, provider networks, and drug formularies can change from year to year. So how might retirees navigate this? 'We have to give people information,' Oz said. 'At the same point, I don't want people to panic and jump to changes." His advice is simple: Do your homework, but don't feel pressured to change plans unless you have a clear reason. One big resource is 1-800-MEDICARE. 'It's easy to remember, and it's got a ton of information,' he said. 'Especially during open enrollment, I strongly urge you to do a little work.' Hospice scams Healthcare scams are on the rise — and Medicare beneficiaries are among the top targets. The CMS recently sounded the alarm in a blog post and video featuring Oz, warning older Americans to be on guard for this disturbing trend. 'Beware of scammers, sometimes posing as salespeople, offering 'free' services or gifts,' the CMS blog warned. 'They may be trying to trick you into signing up for hospice care without your knowledge.' 'This is a reprehensible activity,' Oz said. 'It's run by criminal syndicates — not small-time operators. They take advantage of people at their most vulnerable time.' Hospice fraud is insidious because it targets people making some of the most difficult decisions of their lives. Oz said, 'We are hearing horror stories about people who thought they were entering legitimate hospice and there's nothing there for them. And even worse — because you're not really sick — people are on these hospice programs for years. We're going after them in a big way.' 'There is a new sheriff in town' Oz promised a tougher stance against healthcare fraud, both foreign and domestic. 'We already have actions in several states,' he said. 'The Department of Justice is pursuing a lot of these leads. We will leave no stone unturned. There is a new sheriff in town. I promise you, if you're cheating the American people, we will come after you. And if you're doing it to hurt folks who are most vulnerable — we'll be doubly vigilant.' Beyond enforcement, Oz emphasized that better technology and patient identification are key to preventing fraud before it happens. 'You're talking about an agency with a $1.7 trillion budget,' Oz said. 'One policy memo can affect [tens of millions of Americans.] We have to get it right.' One key will be distilling the complexity of the system into actionable information for both the public and his team. 'The goal is the same as it was" on his TV show, Oz said. "Explain it so people understand it and can act on it,' he said. 'If we simplify the rules, give people clear guidance, and enforce the protections already in place, we can change outcomes for millions of Americans." Got questions about retirement? Email Robert Powell at yfpodcast@ and we'll do our best to answer it in a future episode of Decoding Retirement. Each Tuesday, retirement expert and financial educator Robert Powell gives you the tools to plan for your future on Decoding Retirement. You can find more episodes on our video hub or watch on your preferred streaming service. Sign up for the Mind Your Money newsletter Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Recombinant Human Hair Keratin Protein Market 2025 Trends and Updates
The global recombinant human hair keratin protein market is growing quickly as more people seek effective hair health solutions and advanced wound healing treatments, says a study published by Towards Healthcare a sister firm of Precedence Research. Ottawa, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The global recombinant human hair keratin protein market is on a strong growth trajectory, with revenues expected to climb into the hundreds of millions by 2034. This momentum is being fueled by a rising focus on hair health, a noticeable increase in bleeding disorder cases, and a wave of fresh investments pouring into biotechnology. Together, these factors are creating fertile ground for innovation and demand across multiple industries. Companies in North America, Asia-Pacific, and Europe are actively investing in research, driving innovations, and forming partnerships to open new market opportunities. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ Key Takeaways North America dominated the recombinant human hair keratin protein market in 2024. Asia Pacific is estimated to grow at the fastest CAGR during the forecast period. Market Overview & Potential Recombinant human hair keratin protein is a lab-engineered protein that replicates the structure and function of natural keratin in human hair. It is produced via recombinant DNA technology, resulting in a highly controlled and pure form of keratin that differs from traditional extracts. This makes it a valuable material for applications such as wound healing and hair care. Conventional keratin extraction methods can be inconsistent and may not yield pure products, whereas recombinant production ensures greater purity and enables precise control over the protein's amino acid sequence and structure, resulting in more predictable properties. Top Countries in Recombinant Human Hair Keratin Protein Market: United States Contribution: Leading the global market with strong demand for medical-grade recombinant keratin, supported by a robust biotech ecosystem and healthcare infrastructure. Strength: Advanced R&D capabilities and regulatory support for therapeutic and regenerative applications. China Contribution: Fastest-growing market, fueled by a rapidly expanding cosmetics and personal care sector. Strength: Strong domestic production capabilities, rising consumer awareness, and increasing investment in biotech innovations. Germany Contribution: Key contributor in Europe, especially in high-purity recombinant keratin for medical and cosmetic formulations. Strength: Expertise in biotechnology and demand for premium, high-performance personal care products. France Contribution: Strong market for cosmetic applications, particularly in haircare and skincare products incorporating natural bioactive ingredients. Strength: Sophisticated beauty industry and preference for sustainable, biologically derived ingredients. India Contribution: Emerging player in both medical and cosmetic applications of recombinant keratin. Strength: Large population base, rising demand for advanced hair and skin treatments, and growing domestic manufacturing activity. You can place an order or ask any questions, please feel free to contact us at sales@ What is the Growth Potential Responsible for The Growth of The Recombinant Human Hair Keratin Protein Market? The growth of the market is driven by the growing application in the biomedical field due to its biocompatibility, ability to promote cell growth, and biodegradability, which makes it ideal for various medical uses, driving the growth. The key applications, like tissue regeneration, drug delivery systems, and wound healing, are supporting the growth of the market. Other key drivers are biotechnology research due to the growing biotechnology sector, in personal care and cosmetics, and sustainable and ethical sourcing. Increasing incidence of chronic diseases, and government initiatives in R&D in life sciences research and development. What Are the Growing Trends Associated with the Recombinant Human Hair Keratin Protein Market? The technological advancements like innovation in synthetic biology and demonstration technology for the development of new and tailored properties, and more efficient production methods. Rising demand in the cosmetic sector for the development of hair care products for improving the shine, strengthening the damaged hair, and reducing the frizz increases the demand for the product. The growing biomedical applications, like in wound healing, tissue engineering, and drug delivery, fuel the demand for the product, supporting the growth. Shift towards sustainable and ethical products, like growing demand and interest in vegan and plant-based keratins, improves the market growth of the market. Increasing awareness and adoption due to the benefits offered and availability of the products make it a preferred choice, and increase the growth. What Is the Growing Challenge in the Recombinant Human Hair Keratin Protein Market? However, the recombinant human hair keratin protein market faces challenges including production issues, consistency concerns, and consumer perceptions. Although recombinant technology provides advantages like higher purity and specific amino acid composition, it also risks problems like misfolding, aggregation, and low yields. Additionally, high production costs, especially due to specialized equipment and chemicals, can hinder market growth. Consumer preferences for natural or plant-based products, along with safety and efficacy concerns regarding keratin treatments, could also limit market expansion. Get the latest insights on life science industry segmentation with our Annual Membership: Regional Analysis How Did North America Dominate the Recombinant Human Hair Keratin Protein Market in 2024? North America led the recombinant human hair keratin protein market in 2023. Growth is driven by increased investments, collaborations, key industry players, and advanced R&D activities. The US and Canada are the primary markets, with companies like Novus Biologicals, Abcam Ltd., PROGEN, and OriGene contributing significantly. US government initiatives to promote biotech research further boost the market, complemented by over 130 recombinant proteins approved by the US FDA for clinical use. In the UK, industries are exploring innovative methods to enhance hair growth, quality, and reduce hair fall using recombinant human hair keratin protein. Additionally, rising awareness about hair health is fueling demand for these products. What Made Asia Pacific Significantly Grow in The Recombinant Human Hair Keratin Protein Market in 2024? Asia-Pacific is expected to grow the fastest in the recombinant human hair keratin protein market during the forecast period. Market growth is driven by increasing research and development activities, rising government funding, a growing number of bleeding disorder cases, favorable infrastructure, and lower costs. Recombinant keratin has been shown to promote skin wound healing and improve blood clotting. In China, about 65,000 people suffer from hemophilia, while India has the second-largest number of hemophilia cases worldwide, with 136,000 patients. The demand for products that support hair growth and reduce hair loss is rapidly increasing in China, South Korea, and Japan. Companies like Tsubaki use recombinant human keratin to develop luxurious hair treatments that attract beauty-conscious consumers. Become a valued research partner with us - Recent Developments In July 2024, Yuhan Corp, a South Korean pharmaceutical company, signed a comprehensive R&D collaboration agreement with ProGen. The collaboration was made to strengthen next-generation biologics and drug development research. In April 2024, Bio-Techne Corporation announced a strategic distribution agreement with Thermo Fisher Scientific. The agreement will distribute Bio-Techne's innovative products, such as antibodies, proteins, immunoassay kits, reagents, and enzymes, to laboratories and research institutions across Europe. Browse More Insights of Towards Healthcare: The global GMP grade cytokines market is valued at USD 2.54 billion in 2024, expected to rise to USD 2.79 billion in 2025, and anticipated to reach approximately USD 6.48 billion by 2034. This represents a steady growth trajectory at a CAGR of 9.84% from 2025 to 2034. The global recombinant proteins market is estimated at USD 3.36 billion in 2025 and is forecasted to climb to around USD 8.08 billion by 2034, expanding at a CAGR of 10.24% over the forecast period. The recombinant lysyl endopeptidase market was valued at USD 38 million in 2023 and is projected to reach USD 67.06 million by 2034, growing at a CAGR of 5.3% between 2024 and 2034. The global hair transplant market stands at USD 7.33 billion in 2024, rising to USD 8.87 billion in 2025, with projections indicating a surge to nearly USD 49.44 billion by 2034—signaling rapid expansion. The hair treatment drug market was worth USD 1.4 billion in 2023 and is anticipated to grow to USD 2.99 billion by 2034, recording a CAGR of 7.14% during 2024–2034. The global host cell protein testing market is valued at USD 2.37 billion in 2024, estimated to increase to USD 2.56 billion in 2025, and forecasted to hit USD 5.19 billion by 2034, with an expected CAGR of 8.17% from 2025 to 2034. The global protein expression technology market is pegged at USD 2.85 billion in 2024, projected to rise to USD 3.05 billion in 2025, and likely to reach USD 5.58 billion by 2034, reflecting a CAGR of 6.94% over the forecast timeline. The global proteinase K market is valued at USD 4.82 billion in 2024, forecasted to grow to USD 5.23 billion in 2025, and set to reach USD 10.93 billion by 2034, advancing at a CAGR of 8.54% between 2025 and 2034. The global cell-free protein expression market is valued at USD 315.03 million in 2024, expected to grow to USD 342.25 million in 2025, and projected to hit USD 716.26 million by 2034, expanding at a CAGR of 8.63% from 2025 to 2034. The global protein therapeutics market is calculated at USD 375.3 billion in 2024, projected to grow to USD 401.89 billion in 2025, and expected to reach USD 740.07 billion by 2034, advancing at a CAGR of 7.08% over the forecast period. Recombinant Human Hair Keratin Protein Market Key Players Abcam Limited Abbexa, Ltd. Bon Opus Biosciences Creative Diagnostics MyBioSource, Inc. Novus Biologicals OriGene PROGEN ProSpec Wuhan Huamei Biotech Co., Ltd. Regions Covered North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: Immediate Delivery Available | Buy This Premium Research @ About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. You can place an order or ask any questions, please feel free to contact us at sales@ Europe Region - +44 778 256 0738 North America Region - +1 8044 4193 44 Web: Find us on social platforms: LinkedIn | Twitter | InstagramError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
OhioHealth plans ‘medical use' for Big lots Columbus HQ after $36 million sale
COLUMBUS, Ohio (WCMH) — OhioHealth is taking the next steps to expand services in northeast Columbus after purchasing Big Lots' former headquarters for $36 million. The healthcare provider applied on July 29 to rezone the 24-acre property at 4900 E. Dublin Granville Rd. 'for expanded medical uses,' NBC4 confirmed. The move comes as 'OhioHealth has a significant presence in the New Albany area which includes a major ambulatory facility, an urgent care and a freestanding emergency department,' a spokesperson said. Intel CEO under pressure to resign from President Trump, Ohio Senator Moreno 'As part of our continued interest in growing services in the communities we serve, OhioHealth purchased the former Big Lots' headquarters near New Albany and submitted an application to rezone the property for expanded medical uses,' the spokesperson said in a statement. OhioHealth's effort will position the building to meet a variety of future community healthcare needs, but no specific project is planned or funded at this time, the statement noted. The provider's New Albany footprint includes an emergency care center and a medical campus with an urgent care center along nearby Hamilton Road. Big Lots entered into an agreement with the healthcare provider to sell its headquarters in January, then closed on the $36 million sale in April, Franklin County Auditor's Office records show. The property includes two buildings constructed in 2017 as part of the Hamilton Quarter development. The first building is office space spanning four stories and 273,000 square feet, and the second is 329,348 square feet with distribution space and a parking garage. Once a Columbus-based retailer, Big Lots announced in a city notice last year that 555 employees based at the East Dublin Granville Road headquarters would be terminated. The letter said the 'mass layoffs' were expected to begin the week of Dec. 29 and conclude by April. An Ohio dealership repossessed her car, so she took their name and then sued The agreement with OhioHealth came as Gordon Brother Retail Partners acquired Big Lots in January, which included a deal to transfer the ownership of several hundred storefronts to Variety Wholesalers, a Henderson, North Carolina, company that operates several hundred discount stores. Variety then moved to relaunch dozens of Big Lots stores in waves. The first round reopened nine stores in early April, followed by nearly 60 storefronts in the second wave in May, including seven in Ohio. A third round featured eight Ohio locations, while the final set featured nearly 80 stores, including 13 in Ohio. Big Lots filed for bankruptcy last September and was almost acquired by a top Dollar Shave Club and Toms investor for $765 million before the sale fell through. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
